RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE

Zevra Therapeutics Stocks 2024

Zevra Therapeutics Stocks

35.45 M

Zevra Therapeutics Dividend yield

Ticker

ZVRA

ISIN

US4884452065

WKN

A2QLX7

In 2024, Zevra Therapeutics had 35.45 M outstanding stocks, a 0% change from the 35.45 M stocks in the previous year.

The Zevra Therapeutics Stocks history

YEARNUMBER OF STOCKS (undefined USD)
2029e35.45
2028e35.45
2027e35.45
2026e35.45
2025e35.45
2024e35.45
202335.45
202234.49
202129.77
20203.98
20191.85
20181.12
20170.92
20160.91
20150.46
20140.15
20130.15
20120.15

Zevra Therapeutics Aktienanalyse

What does Zevra Therapeutics do?

KemPharm Inc. is a biopharmaceutical company founded in Iowa in 2006. The company focuses on developing new drugs for the treatment of pain, neurological disorders, and psychiatric disorders. KemPharm uses its own proprietary technology platform to synthesize new drug molecules that have better efficacy, tolerability, and safety than existing medications. The business model of KemPharm is based on the development and commercialization of novel prodrugs. A prodrug is an inactive precursor of a drug that is converted into its active form in the body. KemPharm utilizes its proprietary technology platform to design specific chemical compounds that are converted into the active form by a biological enzyme naturally present in the body. The advantages of such prodrugs are improved bioavailability, longer duration of action, and reduced toxicity. KemPharm has several business divisions: Kempharm Discovery, Kempharm Clinical, Kempharm Licensing, Kempharm Manufacturing, and Kempharm Commercial. Kempharm Discovery is the division where research and development of new drugs are conducted. KemPharm has several prodrugs in the development phase, including KP415, KP484, and KP879, each being developed for the treatment of attention deficit hyperactivity disorder (ADHD), pain, and epilepsy, respectively. KemPharm Clinical is the division where clinical trials and regulatory approval of new drugs are conducted. The company has conducted several phase II and phase III trials for its prodrugs and plans to obtain commercial approval for its first products in the coming years. KemPharm Licensing is the division where KemPharm licenses its technology platform to other companies. The company has already formed several partnerships with other pharmaceutical companies, including Acura Pharmaceuticals, KVK Tech, and Gurnet Point Capital. These partnerships aim to enable the use of KemPharm's prodrugs in other products and increase revenue. Kempharm Manufacturing is the division where KemPharm's drugs are manufactured. KemPharm collaborates with various generic drug manufacturers to produce and distribute its prodrugs. Kempharm Commercial is the division where KemPharm sells its prodrugs directly to patients and physicians. The company plans to sell its prodrugs through pharmaceutical industry distribution and specialized sales channels. Overall, KemPharm has a promising portfolio of prodrugs that have potential for many medical applications. The company has the potential to become a major player in the pharmaceutical industry. KemPharm Inc. is a biopharmaceutical company that was founded in Iowa in 2006. The company focuses on developing new drugs for the treatment of pain, neurological disorders, and psychiatric disorders. KemPharm utilizes its proprietary technology platform to synthesize new drug molecules that have better efficacy, tolerability, and safety compared to existing medications. KemPharm's business model is based on the development and commercialization of novel prodrugs. A prodrug is an inactive precursor of a drug that is converted into its active form within the body. Using its proprietary technology platform, KemPharm designs specific chemical compounds that can be converted into their active forms by a naturally occurring biological enzyme within the body. The advantages of these prodrugs include improved bioavailability, longer duration of action, and reduced toxicity. KemPharm operates in several business areas: Kempharm Discovery, Kempharm Clinical, Kempharm Licensing, Kempharm Manufacturing, and Kempharm Commercial. Kempharm Discovery is responsible for the research and development of new drugs. KemPharm currently has several prodrugs in the developmental stage, such as KP415, KP484, and KP879, each designed for the treatment of attention deficit hyperactivity disorder (ADHD), pain, and epilepsy, respectively. KemPharm Clinical is responsible for conducting clinical studies and obtaining regulatory approval for new drugs. The company has conducted multiple phase II and phase III studies for its prodrugs and plans to obtain commercial approval for its first products in the upcoming years. KemPharm Licensing is responsible for licensing KemPharm's technology platform to other companies. The company has already formed partnerships with other pharmaceutical companies, including Acura Pharmaceuticals, KVK Tech, and Gurnet Point Capital. These partnerships enable the utilization of KemPharm's prodrugs in other products and contribute to revenue growth. Kempharm Manufacturing is responsible for the production of KemPharm's drugs. The company collaborates with various generic drug manufacturers to produce and distribute its prodrugs. Kempharm Commercial is responsible for the direct sales of KemPharm's prodrugs to patients and physicians. The company plans to sell its prodrugs through pharmaceutical industry distribution channels and specialized distribution channels. Overall, KemPharm has a promising portfolio of prodrugs with potential applications in various medical fields. The company has the potential to become a significant player in the pharmaceutical industry. Zevra Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Stocks Details

Evaluating Zevra Therapeutics's Shares Outstanding

Zevra Therapeutics's shares outstanding refer to the total number of shares that are currently held by all its shareholders, including institutional investors and restricted shares held by the company’s officers and insiders. The number of shares outstanding is crucial in determining the company's market capitalization and is used by investors to assess the company’s size, financial health, and investment potential.

Year-to-Year Comparison

Tracking the changes in Zevra Therapeutics’s shares outstanding over the years can provide investors with insights into the company's financial strategies and market valuation. An increase in shares outstanding can result from actions like issuing new shares, while a decrease can result from buybacks.

Impact on Investments

For investors, understanding Zevra Therapeutics’s shares outstanding is essential for evaluating its earnings per share (EPS) and market valuation. A change in the number of shares outstanding can impact the EPS, which is a significant driver of stock prices and investor decisions.

Interpreting Changes in Shares Outstanding

Variances in Zevra Therapeutics’s shares outstanding can signal shifts in the company’s financial strategy. An increase may dilute the EPS and share value, indicating potential fundraising or acquisitions. Conversely, a decrease, often due to share buybacks, can enhance share value and indicate the company’s confidence in its financial performance.

Frequently Asked Questions about Zevra Therapeutics Stock

How many stocks are there of Zevra Therapeutics?

The current number of stocks of Zevra Therapeutics is 35.45 M undefined.

What does Number of Shares / OutstandingShares mean?

The outstanding shares (or issued shares) of Zevra Therapeutics are the total number of shares issued and actively held by shareholders - both external investors and company insiders. However, these must be actual shares. may grant stock options to executives that can be converted into shares.

How has the number of shares of Zevra Therapeutics evolved in recent years?

The number of shares of Zevra Therapeutics has increased by 0% gestiegen compared to last year.

What does the number of shares mean for investors?

The number of shares outstanding is used to calculate key metrics such as a company's market capitalization, earnings per share (EPS), and cash flow per share (CFPS). The number of outstanding shares of a company is not static and can fluctuate greatly over time.

Why does the number of stocks fluctuate?

There are various factors that can lead to a change. Zevra Therapeutics as a company can issue new shares, carry out stock splits or reverse splits.

Does the number of shares have an impact on the performance of Zevra Therapeutics?

There is no tangible long-term evidence or study that stocks with a certain number of shares (regardless of Mega/Large/Mid/Small Cap) would yield significantly higher returns than others. There are occasional small studies (limited number of stocks, short investment period) that certain classes outperform or have higher risk, but none of them are 1. conclusive (cause-effect is unclear, experiment is not repeatable) or 2. generalizable (generalization is not possible due to small sample size and time period).

How much dividend does Zevra Therapeutics pay?

Over the past 12 months, Zevra Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Zevra Therapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of Zevra Therapeutics?

The current dividend yield of Zevra Therapeutics is .

When does Zevra Therapeutics pay dividends?

Zevra Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Zevra Therapeutics?

Zevra Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Zevra Therapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Zevra Therapeutics located?

Zevra Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Zevra Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Zevra Therapeutics from 5/10/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 5/10/2024.

When did Zevra Therapeutics pay the last dividend?

The last dividend was paid out on 5/10/2024.

What was the dividend of Zevra Therapeutics in the year 2023?

In the year 2023, Zevra Therapeutics distributed 0 USD as dividends.

In which currency does Zevra Therapeutics pay out the dividend?

The dividends of Zevra Therapeutics are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Zevra Therapeutics

Our stock analysis for Zevra Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Zevra Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.